Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study
Top Cited Papers
- 1 January 2008
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 128 (1) , 35-44
- https://doi.org/10.1038/sj.jid.5701033
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepilepticsNeurology, 2005
- Stevens-Johnson Syndrome after SertralineActa Dermato-Venereologica, 1999
- Toxic Epidermal Necrolysis From AtorvastatinJAMA, 1998
- Toxic epidermal necrolysisThe Lancet, 1998
- Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registryJournal of Clinical Epidemiology, 1996
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995
- An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methodsJournal of Clinical Epidemiology, 1995
- Severe Adverse Cutaneous Reactions to DrugsNew England Journal of Medicine, 1994
- Stevens-Johnson syndrome after terbinafine therapyJournal of the American Academy of Dermatology, 1994
- Stevens-Johnson syndrome after fluconazoleThe Lancet, 1991